Advertisement
Advertisement

BLRX

BLRX logo

BioLineRX Ltd

2.71
USD
Sponsored
0.00
+0.07%
Aug 10, 16:00 UTC -4
Closed
exchange

After-Market

2.73

+0.02
+0.66%

BioLineRX Ltd Profile

About

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.

Info & Links

CEO

Philip A. Serlin

Headquarters

2 HAMA-AYAN STREET, MODI-IN TECHNOLOGY PARK
MODI-IN, L3 7177871, ISRAEL

Industry

Medical Drugs

Sector

Medical

Website

www.biolinerx.com

Auditor

Kesselman & Kesselman

Share holders

--

Employees

24

BioLineRX Ltd Statistics

Valuation Measures

Market Capitalization2

11.88M

Enterprise Value

17.21M

Enterprise Value/EBITDA(ttm)

-1.65

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

8.44

Price to Book(mrq)

0.57

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

79.03%

Operating Margin(ttm)

-563.70%

Profit Margin(ttm)

-643.60%

Return on Equity(ttm)

-37.73%

Return on Invested Capital(ttm)

-37.33%

Return on Assets(ttm)

-19.42%

Income Statement

Revenue(ttm)

1.40M

Revenue Per Share(ttm)

--

Gross Profit(ttm)

1.11M

EBITDA(ttm)3

-10.45M

Net Income Available to Common(ttm)

-7.90M

Diluted EPS(ttm)

-1.92

Share Statistics

Beta (5Y Monthly)

1.54

52-Week Change

-23.82%

S&P 500 52-Week Change

21.65%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

--

Dividend Yield

0.00%

Float4

4.32M

% Held by Insiders

1.10%

% Held by Institutions

1.56%

Balance Sheet

Total Cash(mrq)

17.35M

Total Cash Per Share(mrq)

--

Total Debt(mrq)

7.84M

Total Debt/Equity(mrq)

37.62%

Current Ratio(mrq)

1.58%

Quick Ratio(mrq)

1.43%

Book Value Per Share(mrq)

4.79

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.51

Free Cash Flow(ytd)

-2.29M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement